<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=5442258&amp;fmt=gif">
Skip to content

Accelerating drug development and manufacturing

GL CHEMTEC is your trusted CDMO partner for API development and tailored polymers for drug delivery. 

Custom solutions for APIs and biomedical materials

SmallMoleculeIcon (002)
Small Molecule API Development

Synthetic route development and optimization, early-process scale-up of API targets and RSMs.


Tailored Biomedical Polymers

Novel biomedical polymers and hydrogels to enhance drug delivery and medical device applications. 


Integrated Solutions

Full-spectrum solutions combining small molecule API development and tailored polymers for delivery.


Test tubes


As an independent, founder-led life sciences company, GL CHEMTEC is passionate about your success and committed to solving your most complex chemistry challenges. We are fast and flexible, and our collaborative partnership approach means that we scale and adapt according to your needs.

A next-level API partner  

offering a unique combination of small molecule and polymer expertise.

Tackle complex chemistry challenges

with our deep expertise in small molecule chemistry and tailored polymers, and a collaborative approach.

Drive innovation with a green chemistry mindset

committed to sustainability and green chemistry best practices. 

IntegratedSolutionsIcon (002)
Accelerate early-stage API development and innovative drug delivery solutions 

with seamless continuity from R&D to manufacturing.

North American location and security of supply  

offering an alternative to traditional supply chains and overseas partners.

Highly customer-centric culture   

reflected by our 22 years of success in life sciences, delivering innovative solutions with unrivalled speed, agility, and passion.


Established in 2002, GL CHEMTEC is a leading, independent CRO/CDMO partner. We provide innovative solutions and technologies to various industries, including pharmaceutical, biotech, medical device/biomedical materials, ophthalmology, and tailored polymers. Our comprehensive services cover almost all areas of the drug development process, from discovery to manufacturing, utilizing our state-of-the-art facilities in North America.

At GL CHEMTEC, green chemistry is more than a service, it is a core value that shapes our approaches, processes, and operations. We are proud of our enduring partnerships with top-tier life science establishments worldwide, constantly striving for excellence in areas such as small molecule R&D, process development, scale-up, green chemistry, and drug delivery.

Customers often approach us with their most important chemistry challenges, and we excel in solving them. With our expertise in small molecule API development and tailored polymers, we offer fast, flexible, and world-class solutions. We encourage you to explore our capabilities, facilities, and to reach out to us for more information. Together, we can accelerate the development of next-generation therapeutics and biomedical materials, ultimately improving the human condition.

Recent blogs


Bell Mid-Sized Business of the Year

Canadian Business Review Board Best Business Award
2021, 2022, 2023, 2024

Winner Magazine - Outstanding Canadian Business

Outstanding Business in Customer Satisfaction, Business Leadership, Outstanding Service, Strong Vision

2024 CBRB GL Chemtec International Badge_resized
2023 CBRB GL Chemtec International Badge_resized
2023 Winner Magazine Medal of Recognition for GL Chemtec - resized
2022 CBRB GL Chemtec International Badge_

ISO Certifications

ISO 13485:2016 – Medical Device & Early Clinical Study Support

ISO 9001:2015 – A Commitment to Quality and Traceability


ISO 13485:2016 – Medical Device & Early Clinical Study Support
ISO 9001:2015 – A Commitment to Quality and Traceability

CCD Partners Pre-Clinical CRO Watchlist

GL CHEMTEC is proud to be highlighted as a top potential disruptor in the pre-clinical CRO space due to exciting recent corporate developments and our potential to impact the industry in the near future.

The Watchlist includes 112 independent players in the pre-clinical CRO space, each of which has the potential to disrupt the established market in the next few years.